Drug interactions between ezetimibe/simvastatin and Miradon
| Results for the following 2 drugs: |
|---|
| ezetimibe/simvastatin |
| Miradon (anisindione) |
Interactions between your selected drugs
anisindione ↔ simvastatin
Applies to:Miradon (anisindione) and ezetimibe/simvastatin
Simvastatin may slightly increase the anticoagulant response to warfarin. The mechanism may be warfarin displacement from protein binding sites. The clinical significance of this interaction has not been established, however, clinical monitoring of patient warfarin response and tolerance is recommended. Simvastatin may interact in a similar way with other oral anticoagulants. In addition, a case study has reported reversible rhabdomyolysis and acute renal failure 7 days following initiation of warfarin in a patient stabilized on simvastatin. Pravastatin, another HMG-CoA reductase inhibitor, does not appear to affect anticoagulation. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
anisindione ↔ ezetimibe
Applies to:Miradon (anisindione) and ezetimibe/simvastatin
In a study of 12 healthy adult males, coadministration of ezetimibe (10 mg once daily) had no significant effect on the bioavailability of warfarin or prothrombin time. Increased International Normalized Ratio (INR) has been reported during postmarketing use of ezetimibe in patients who had it added to warfarin. However, most of these patients were also on other medications, so the relationship to ezetimibe is uncertain. Ezetimibe product labeling recommends that the INR be appropriately monitored if ezetimibe is used in patients receiving warfarin. The effect of ezetimibe on other oral anticoagulants is unknown.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
